Source comparison
Tesamorelin + Ipamorelin Blend Work: Comparison Across Research Models
Peak GH Response (ng/mL) 5.8–7.2 ng/mL at 60–90 min 6.1–7.8 ng/mL at 45–75 min 16.4–18.4 ng/mL at 60–90 min The blend produces synergistic GH elevation 2.5–3.2× higher than monotherapy. Critical for protocols requiring robust, reproducible GH peaks. Cortisol E
This comparison does not assign a generated winner or score.
- Peak GH Response (ng/mL)
- 5.8–7.2 ng/mL at 60–90 min
- 6.1–7.8 ng/mL at 45–75 min
- 16.4–18.4 ng/mL at 60–90 min
- The blend produces synergistic GH elevation 2.5–3.2× higher than monotherapy. Critical for protocols requiring robust, reproducible GH peaks.
- Cortisol Elevation
- Minimal (<8% above baseline)
- Minimal (<5% above baseline)
- Minimal (<6% above baseline)
- All three options avoid the ACTH-mediated cortisol spike seen with older secretagogues. Metabolic confounders are eliminated.
- Pulsatility Preservation
- Yes. Mimics endogenous GHRH pulses
- Yes. But shorter duration (90–120 min)
- Yes. Extended pulse duration (120–180 min)
- The combination extends GH elevation without flattening the pulse into continuous secretion, preserving hepatic GH receptor sensitivity.
- Receptor Desensitisation Risk
- Moderate. GHRH receptor downregulation after 14–21 days of daily dosing
- Low. GHSR1a shows minimal desensitisation
- Low. Dual-pathway activation distributes receptor load
- Long-term protocols (>12 weeks) benefit from the blend's ability to maintain response without escalating dose.
- Metabolic Research Utility
- Strong for VAT reduction, moderate for lean mass accretion
- Moderate for both VAT and lean mass
- Strongest. Synergistic lipolysis and anabolic signaling
- The blend's amplified GH response translates to greater IGF-1 elevation and downstream metabolic effects in 12–24 week studies.